Can a pill rewrite the genetic story of resistant kidney cancer?
NCT ID NCT07748988
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This pilot study tests whether the experimental drug casdatifan can alter the activity of genes controlled by HIF-2α in people with advanced clear cell kidney cancer that has stopped responding to prior treatments. Participants take casdatifan daily, and researchers analyze tumor biopsies taken before, during, and after treatment to see how gene expression shifts. The goal is to understand how the drug works and why some tumors may resist it, potentially guiding smarter use of this therapy in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- casdatifan (AB521), an oral HIF-2α inhibitor
- What this could lead to
- If successful, this could reveal how casdatifan works in resistant kidney cancer and guide future combination therapies or patient selection.
- What could go wrong
- This is a very early, small pilot study focused on biological changes, not clinical outcomes. Results may not predict treatment effectiveness, and tumor biopsies carry procedural risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- New PET scan could reveal kidney cancer drug success in weeks, not months
- Custom-Made vaccine aims to boost immune attack on kidney tumors
- New scan could reveal hidden kidney cancer